BE2013C036I2 - - Google Patents

Download PDF

Info

Publication number
BE2013C036I2
BE2013C036I2 BE2013C036C BE2013C036C BE2013C036I2 BE 2013C036 I2 BE2013C036 I2 BE 2013C036I2 BE 2013C036 C BE2013C036 C BE 2013C036C BE 2013C036 C BE2013C036 C BE 2013C036C BE 2013C036 I2 BE2013C036 I2 BE 2013C036I2
Authority
BE
Belgium
Application number
BE2013C036C
Original Assignee
Sanofi Mature Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34224354&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2013C036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Mature Ip filed Critical Sanofi Mature Ip
Publication of BE2013C036I2 publication Critical patent/BE2013C036I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
BE2013C036C 2003-09-19 2013-06-13 BE2013C036I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0311016A FR2859996B1 (fr) 2003-09-19 2003-09-19 Solvat acetonique du dimethoxy docetaxel et son procede de preparation
PCT/FR2004/002344 WO2005028462A1 (fr) 2003-09-19 2004-09-16 Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Publications (1)

Publication Number Publication Date
BE2013C036I2 true BE2013C036I2 (fr) 2023-12-14

Family

ID=34224354

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2013C036C BE2013C036I2 (fr) 2003-09-19 2013-06-13

Country Status (38)

Country Link
US (1) US7241907B2 (fr)
EP (1) EP1667986B1 (fr)
JP (1) JP5010279B2 (fr)
KR (1) KR101123588B1 (fr)
CN (1) CN100429207C (fr)
AR (1) AR045667A1 (fr)
AU (1) AU2004274212B2 (fr)
BE (1) BE2013C036I2 (fr)
BR (1) BRPI0414492A8 (fr)
CA (1) CA2539309A1 (fr)
CR (1) CR8292A (fr)
CY (2) CY1114575T1 (fr)
DK (1) DK1667986T3 (fr)
ES (1) ES2403149T4 (fr)
FR (1) FR2859996B1 (fr)
HK (1) HK1093340A1 (fr)
HR (1) HRP20130322T1 (fr)
HU (1) HUS1300025I1 (fr)
IL (1) IL174240A (fr)
LU (1) LU92172I2 (fr)
MA (1) MA28045A1 (fr)
ME (2) ME00054B (fr)
MX (1) MXPA06002639A (fr)
MY (1) MY136668A (fr)
NO (2) NO335997B1 (fr)
NZ (1) NZ545835A (fr)
PA (1) PA8612401A1 (fr)
PE (1) PE20050870A1 (fr)
PL (1) PL1667986T3 (fr)
PT (1) PT1667986E (fr)
RS (2) RS54614B1 (fr)
RU (1) RU2342373C2 (fr)
SI (1) SI1667986T1 (fr)
TN (1) TNSN06086A1 (fr)
TW (1) TWI382022B (fr)
UA (1) UA87115C2 (fr)
WO (1) WO2005028462A1 (fr)
ZA (1) ZA200602255B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533330A (ja) * 2006-03-21 2009-09-17 ドクター レディズ ラボラトリーズ リミテッド ドセタキセルの多形体およびプロセス
US7855591B2 (en) * 2006-06-07 2010-12-21 Atmel Corporation Method and system for providing a charge pump very low voltage applications
US7652522B2 (en) * 2006-09-05 2010-01-26 Atmel Corporation High efficiency low cost bi-directional charge pump circuit for very low voltage applications
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
FR2926551A1 (fr) 2008-01-17 2009-07-24 Aventis Pharma Sa Formes cristallines du dimethoxy docetaxel et leurs procedes de preparation
AU2013205442B2 (en) * 2008-01-17 2016-05-12 Aventis Pharma S.A. Crystalline forms of dimethoxy docetaxel and methods for preparing same
CA2732508C (fr) 2008-08-11 2016-03-15 Nektar Therapeutics Conjugues d'alcanoate polymere a multiples bras
FR2945211A1 (fr) 2009-05-06 2010-11-12 Sanofi Aventis Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
AU2015200149B2 (en) * 2009-10-29 2016-12-01 Aventis Pharma S.A. Novel antitumoral use of cabazitaxel
PE20121429A1 (es) * 2009-10-29 2012-11-06 Aventis Pharma Sa Nuevo uso antitumoral de cabazitaxel
CA2708489A1 (fr) * 2009-10-29 2011-04-29 Aventis Pharma S.A. Utilisation de cabazitaxel et de prednisone ou de prednisolone pour traiter le cancer de la prostate
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
EP2688877B1 (fr) 2011-04-12 2017-03-08 Teva Pharmaceuticals International GmbH Formes solides de cabazitaxel et procédés de préparation associés
WO2013024495A1 (fr) * 2011-08-18 2013-02-21 Dr. Reddys Laboratories Limited Formulations pharmaceutiques de cabazitaxel
TWI526437B (zh) * 2011-09-09 2016-03-21 台灣神隆股份有限公司 卡巴他賽之結晶型
WO2013072766A2 (fr) 2011-10-31 2013-05-23 Scinopharm Taiwan, Ltd. Procédé de fabrication de cabazitaxel et de ses intermédiaires
DE112012004569T5 (de) 2011-11-01 2014-08-14 Fresenius Kabi Oncology Ltd. Amorphe Form von Cabazitaxel und Verfahren zum Herstellen davon
ES2716799T3 (es) 2011-11-28 2019-06-17 Fresenius Kabi Oncology Ltd Forma cristalina de cabazitaxel y proceso para la preparación de la misma
JP6025861B2 (ja) 2011-12-13 2016-11-16 アベンティス・ファーマ・ソシエテ・アノニム カバジタキセルの結晶形およびこれを調製するための方法
WO2013111157A1 (fr) * 2012-01-03 2013-08-01 Shilpa Medicare Limited Procédé de préparation de cabazitaxel amorphe
CN104334172A (zh) * 2012-02-10 2015-02-04 安万特医药股份有限公司 卡巴利他索(cabazitaxel)之新颖小儿药用途
EP2822932A2 (fr) 2012-03-08 2015-01-14 IVAX International GmbH Formes à l'état solide de cabazitaxel et procédés pour les préparer
CN102675257B (zh) * 2012-05-10 2014-07-02 上海金和生物技术有限公司 一种卡巴他赛晶体及其制备方法
CN102746258B (zh) 2012-07-25 2015-02-04 重庆泰濠制药有限公司 卡巴他赛的结晶形式及其制备方法
EP2880021A4 (fr) 2012-07-31 2015-06-17 Yung Shin Pharm Ind Co Ltd Cabazitaxel amorphe
TWI599373B (zh) 2012-08-15 2017-09-21 永信藥品工業股份有限公司 卡巴利他索（ｃａｂａｚｉｔａｘｅｌ）之穩定醫藥調配物
CN103664836B (zh) * 2012-09-20 2016-04-20 齐鲁制药有限公司 7β,10β-二甲氧基多西紫杉醇氘代丙酮合物的晶型A及其制备方法
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
CN103804323A (zh) * 2012-11-14 2014-05-21 上海希迈医药科技有限公司 一种卡巴他赛溶剂化物及其制备方法和应用
CN103058960B (zh) * 2012-12-12 2014-12-10 江苏奥赛康药业股份有限公司 卡巴他赛多晶型形式及其制备方法
EP2743264A1 (fr) 2012-12-13 2014-06-18 INDENA S.p.A. Nouvelle forme cristalline de cabazitaxel, procédé de préparation et ses compositions pharmaceutiques
CN103910696B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛异丙醚合物及其结晶
CN103910698B (zh) * 2012-12-30 2016-01-20 上海医药工业研究院 卡巴他赛丙酮合物及其结晶
EP2777691A1 (fr) 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoïde - purification des excipients liquides
EP2815749A1 (fr) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Forme solide de 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione ayant un réseau de diffraction de rayons X spécifique
WO2015000165A1 (fr) * 2013-07-04 2015-01-08 北京新天宇科技开发有限公司 Produit de transformation stable du mono-acétonate de dimethoxy docetaxel et ses formes cristallines, et leurs procédés de préparation
CN104277014A (zh) * 2013-07-04 2015-01-14 北京新天宇科技开发有限公司 二甲氧基多西紫杉醇一丙酮化物的稳定转化物及其结晶形式、以及它们的制备方法
EP2865674A1 (fr) 2013-10-23 2015-04-29 INDENA S.p.A. Formes dissoutes cristallines de Cabazitaxel
EP2865675A1 (fr) 2013-10-23 2015-04-29 INDENA S.p.A. Forme cristalline anhydre de Cabazitaxel, procédé de préparation et ses compositions pharmaceutiques
CN103601704B (zh) * 2013-11-22 2015-05-06 石家庄智恒医药科技有限公司 无定形卡巴他赛的制备
ES2904505T3 (es) 2015-01-12 2022-04-05 Emcure Pharmaceuticals Ltd Formulación líquida de cabazitaxel
JP6841772B2 (ja) 2015-02-17 2021-03-10 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 前立腺癌の処置におけるカバジタキセルの使用
EP3093014A1 (fr) * 2015-05-13 2016-11-16 Aventis Pharma S.A. Cabazitaxel et son utilisation pour le traitement du cancer
US10188626B2 (en) 2015-11-03 2019-01-29 Cipla Limited Stabilized cabazitaxel formulations
JP7148532B2 (ja) 2016-11-29 2022-10-05 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピプテリンの多形
KR102561697B1 (ko) 2016-11-29 2023-07-28 피티씨 테라퓨틱스 엠피, 인크. 세피아프테린의 다형체 및 그의 염
JP2020532535A (ja) 2017-09-01 2020-11-12 ピーティーシー セラピューティクス エムピー，インコーポレイテッド セピアプテリンを含む医薬組成物及びその使用
AU2019277382A1 (en) 2018-05-30 2021-01-21 Ptc Therapeutics Mp, Inc. Methods for increasing sepiapterin plasma exposure
WO2020249507A1 (fr) 2019-06-11 2020-12-17 Indena S.P.A. Forme cristalline anhydre du cabazitaxel, procédé pour sa préparation et compositions pharmaceutiques la contenant
EP3797834A1 (fr) 2019-09-25 2021-03-31 Sanofi Mature IP Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène
EP3808345A1 (fr) 2019-10-15 2021-04-21 Sanofi Mature IP Cabazitaxel chez des patients atteints d'un cprcm précédemment traités avec du docétaxel et qui ont résisté à un traitement antérieur impliquant un agent inhibiteur ciblé de la signalisation d'androgène

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
MA23823A1 (fr) * 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2745814B1 (fr) * 1996-03-06 1998-04-03 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2771092B1 (fr) 1997-11-18 1999-12-17 Rhone Poulenc Rorer Sa Procede de preparation de derives de la classe des taxoides
EP0982027A1 (fr) * 1998-08-17 2000-03-01 Aventis Pharma S.A. Dérivés taxoides pour traiter les proliférations cellulaires anormales du cerveau
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
US6136989A (en) * 1998-12-30 2000-10-24 Phytogen Life Sciences, Incorporated Method for high yield and large scale extraction of paclitaxel from paclitaxel-containing material
US5969165A (en) * 1999-01-07 1999-10-19 508037 (Nb) Inc. Isolation and purification of paclitaxel and other related taxanes by industrial preparative low pressure chromatography on a polymeric resin column
ES2211550T3 (es) * 1999-05-17 2004-07-16 Bristol-Myers Squibb Company Nuevas condiciones de reaccion para la escision de eteres de sililo en la preparacion de paclitaxel (taxol(r)) y analogos de paclitaxel.
WO2003045953A1 (fr) * 2001-11-29 2003-06-05 Daiichi Pharmaceutical Co., Ltd. Cristaux de derive de taxane et procede de production associe

Also Published As

Publication number Publication date
MA28045A1 (fr) 2006-07-03
SI1667986T1 (sl) 2013-05-31
WO2005028462A1 (fr) 2005-03-31
PT1667986E (pt) 2013-04-24
ZA200602255B (en) 2007-07-25
JP5010279B2 (ja) 2012-08-29
AU2004274212A1 (en) 2005-03-31
NO2015013I1 (no) 2015-05-04
ME00054B (me) 2011-02-10
FR2859996B1 (fr) 2006-02-03
CY2013016I2 (el) 2018-01-10
RU2342373C2 (ru) 2008-12-27
KR101123588B1 (ko) 2012-03-22
JP2007505866A (ja) 2007-03-15
ES2403149T4 (es) 2013-06-24
LU92172I9 (fr) 2019-01-03
UA87115C2 (ru) 2009-06-25
US7241907B2 (en) 2007-07-10
LU92172I2 (fr) 2013-05-21
MEP11708A (en) 2010-06-10
TNSN06086A1 (en) 2007-10-03
US20050065138A1 (en) 2005-03-24
TW200524891A (en) 2005-08-01
RU2006113122A (ru) 2006-08-27
HRP20130322T1 (en) 2013-07-31
CY2013016I1 (el) 2018-01-10
PE20050870A1 (es) 2005-11-21
TWI382022B (zh) 2013-01-11
HUS1300025I1 (hu) 2016-08-29
CY1114575T1 (el) 2016-10-05
RS54614B1 (en) 2016-08-31
DK1667986T3 (da) 2013-05-06
NO2015013I2 (no) 2015-04-22
CN100429207C (zh) 2008-10-29
AU2004274212B2 (en) 2010-03-04
NO20061714L (no) 2006-04-19
RS20060189A (en) 2008-06-05
PA8612401A1 (es) 2005-08-04
CR8292A (es) 2008-10-15
MY136668A (en) 2008-11-28
NZ545835A (en) 2009-10-30
KR20060072147A (ko) 2006-06-27
NO335997B1 (no) 2015-04-20
EP1667986B1 (fr) 2013-01-16
FR2859996A1 (fr) 2005-03-25
PL1667986T3 (pl) 2013-06-28
CA2539309A1 (fr) 2005-03-31
BRPI0414492A (pt) 2006-11-14
IL174240A (en) 2010-12-30
MXPA06002639A (es) 2006-06-05
BRPI0414492A8 (pt) 2019-01-15
CN1849311A (zh) 2006-10-18
AR045667A1 (es) 2005-11-02
IL174240A0 (en) 2006-08-01
ES2403149T3 (es) 2013-05-14
EP1667986A1 (fr) 2006-06-14
HK1093340A1 (en) 2007-03-02

Similar Documents

Publication Publication Date Title
BE2015C007I2 (fr)
BE2014C055I2 (fr)
BE2014C027I2 (fr)
BE2014C003I2 (fr)
BE2013C075I2 (fr)
BE2013C070I2 (fr)
BE2013C067I2 (fr)
BE2013C038I2 (fr)
BE2013C036I2 (fr)
BE2011C030I2 (fr)
JP2003264750A5 (fr)
JP2003299663A5 (fr)
JP2004096725A5 (fr)
JP2004086136A5 (fr)
JP2003255117A5 (fr)
BE2015C005I2 (fr)
BE2012C053I2 (fr)
JP2003271569A5 (fr)
JP2003319256A5 (fr)
JP2003305227A5 (fr)
BE2015C024I2 (fr)
AU2001256599A1 (fr)
AU2002355123A1 (fr)
AU2002239060A1 (fr)
JP2004081827A5 (fr)